Authors: | Rivière, I.; Sadelain, M. |
Article Title: | Chimeric antigen receptors: A cell and gene therapy perspective |
Abstract: | Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T lymphocytes to target chosen antigens. The targeting of CD19, a cell surface molecule expressed in the vast majority of leukemias and lymphomas, has been successfully translated in the clinic, earning CAR therapy a special distinction in the selection of “cancer immunotherapy” by Science as the breakthrough of the year in 2013. CD19 CAR therapy is predicated on advances in genetic engineering, T cell biology, tumor immunology, synthetic biology, target identification, cell manufacturing sciences, and regulatory compliance—the central tenets of CAR therapy. Here, we review two of these foundations: the genetic engineering approaches and cell types to engineer. © 2017 The American Society of Gene and Cell Therapy |
Keywords: | leukemia; review; nonhuman; t cells; t lymphocyte; cancer immunotherapy; protein targeting; acute lymphoblastic leukemia; rna; regulatory t lymphocyte; lymphocyte activation; dna; immunotherapy; genetic engineering; lymphoma; gene therapy; lentivirus vector; retrovirus vector; chimeric antigen receptor; cell therapy; pluripotent stem cell; lymphoid progenitor cell; cd19 antigen; transposon; tumor immunology; phase 1 clinical trial (topic); lymphocyte subpopulation; synthetic biology; vectors; cell engineering; car; human; genome editing; gene editing |
Journal Title: | Molecular Therapy |
Volume: | 25 |
Issue: | 5 |
ISSN: | 1525-0016 |
Publisher: | Nature Publishing Group |
Date Published: | 2017-05-03 |
Start Page: | 1117 |
End Page: | 1124 |
Language: | English |
DOI: | 10.1016/j.ymthe.2017.03.034 |
PROVIDER: | scopus |
PMCID: | PMC5417838 |
PUBMED: | 28456379 |
DOI/URL: | |
Notes: | Review -- Export Date: 1 December 2017 -- Source: Scopus |